Clidinium (2.5mg) + Chlordiazepoxide (5mg) + Dicyclomine (10mg) + Ranitidine (150mg) (Medical Monograph)

Overview

A fixed-dose combination (FDC) product designed for the comprehensive management of functional gastrointestinal disorders (FGIDs) like Irritable Bowel Syndrome (IBS) and functional dyspepsia, particularly when associated with significant anxiety. It combines an anticholinergic/antispasmodic (Clidinium & Dicyclomine), an anxiolytic (Chlordiazepoxide), and an H2-receptor antagonist (Ranitidine). This combination aims to address the 'brain-gut axis' dysfunction by reducing visceral hypersensitivity, decreasing smooth muscle spasm, suppressing gastric acid, and alleviating anxiety. Its use is controversial and strictly regulated in India due to the presence of a benzodiazepine (chlordiazepoxide).

The combination exerts a multi-modal action. Clidinium and Dicyclomine competitively inhibit acetylcholine at muscarinic receptors in GI smooth muscle, reducing spasms, motility, and secretions. Chlordiazepoxide potentiates GABAergic inhibition in the CNS (limbic system, reticular formation), producing anxiolytic, sedative, and muscle relaxant effects, indirectly modulating the brain-gut axis. Ranitidine competitively inhibits histamine at H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.